Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
McKesson
Healthtrust
Argus Health
QuintilesIMS
Baxter
US Department of Justice
Medtronic
Fuji

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,265,720

« Back to Dashboard

Which drugs does patent 9,265,720 protect, and when does it expire?

Patent 9,265,720 protects EDLUAR and is included in one NDA.

This patent has nine patent family members in twelve countries.
Summary for Patent: 9,265,720
Title:Pharmaceutical formulations useful in the treatment of insomnia
Abstract: There is provided a formulation suitable for transmucosal administration comprising a short acting hypnotic drug, which formulation provides a measurable plasma concentration of drug within 10 minutes of administration. The formulation is capable of providing sleep on demand, and preferably comprises particles of drug, for example zolpidem or a pharmaceutically-acceptable salt thereof and a mucoadhesion promoting agent, such as sodium carboxymethylcellulose, which particles of drug and mucoadhesive are presented upon the surface of larger carrier particles.
Inventor(s): Pettersson; Anders (Kode, SE), Nystrom; Christer (Stockholm, SE), Bredenberg; Susanne (Uppsala, SE)
Assignee: Orexo AB (Uppsala, SE)
Application Number:11/666,361
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form; Formulation; Device;

Drugs Protected by US Patent 9,265,720

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Mylan Speciality Lp EDLUAR zolpidem tartrate TABLET;SUBLINGUAL 021997-001 Mar 13, 2009 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial METHOD OF TREATING INSOMNIA CHARACTERIZED BY DIFFICULTY WITH SLEEP ONSET ➤ Try a Free Trial
Mylan Speciality Lp EDLUAR zolpidem tartrate TABLET;SUBLINGUAL 021997-002 Mar 13, 2009 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial METHOD OF TREATING INSOMNIA CHARACTERIZED BY DIFFICULTY WITH SLEEP ONSET ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,265,720

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0423800.2Oct 27, 2004
PCT Information
PCT FiledOctober 26, 2005PCT Application Number:PCT/GB2005/004147
PCT Publication Date:May 04, 2006PCT Publication Number: WO2006/046041

Non-Orange Book US Patents Family Members for Patent 9,265,720

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,597,281 Pharmaceutical formulations useful in the treatment of insomnia ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,265,720

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Cyprus 1118414 ➤ Try a Free Trial
Denmark 1807156 ➤ Try a Free Trial
Denmark 2340872 ➤ Try a Free Trial
European Patent Office 1807156 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
US Army
Mallinckrodt
Johnson and Johnson
Boehringer Ingelheim
Colorcon
Fuji
Queensland Health
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.